American Journal of Therapeutics 28, e2999-e318
This is a meta-analysis of 18 randomized controlled treatment trials of ivermectin for COVID-19.
CONCLUSIONS: The meta-analysis found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance.
Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin.
Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
